ANIX

Conviction 59HealthcareScan · Mon, Aug 10, 2026

ANIX$3.25-4.97%

ResistanceSupportVol 14Insider buy

Vol MA14 250.19K

May 11May 28Jun 16Jul 6Jul 23Aug 10

Anixa Biosciences IncPHARMACEUTICAL PREPARATIONSwww.anixa.com ↗

Price3.25

Change-4.97%

Gap-2.92%

Rel volume1.28×

Avg volume270.58K

Avg $ vol941.63K

SMA 203.46

SMA 503.04

SMA 2003.24

Price vs 50+7.06%

Price vs 200+0.33%

MA stackmixed

50/200 cross—

Supertrendup · 2.92

RSI (14)47

MACD hist-0.05

MACD crossbear · 7d

Stoch %K / %D3 / 14

ADX (14)21

+DI / −DI14 / 15

RSI divergence—

MACD divergence—

ATR %+7.04%

ADR %7.27%

52w high5.22

52w low2.35

From 52w high-37.74%

Above 52w low+38.30%

New 52w highNo

SqueezeOn · 1d

Bollinger width14.69%

%B0.09

Donchian pos28.09%

Donchian high3.89

Donchian low3.00

AVWAP (52w high)3.29

vs AVWAP high-1.36%

AVWAP (52w low)3.14

vs AVWAP low+3.42%

OBV trendFlat

Chaikin MF (20)-0.13

Today vs 20d1.28×

Avg vol (14d)250.19K

Avg vol (20d)270.58K

Avg $ vol (20d)941.63K

Market cap—

RS 3m (vs SPY)+9.84%

RS 6m (vs SPY)+10.25%

RS line new highNo

Trend template4/8

Technical rank57.9

1 week-4.69%

1 month+6.21%

3 months+8.33%

6 months+9.80%

1 year+7.97%

YTD+2.85%

P/E-10.71

P/B8.09

P/S557.33

P/FCF-16.28

EPS-0.3400

Div yield—

ROE-75.49%

ROA-73.51%

Debt/Eq0.03

Current9.79

EV/EBITDA-9.92

Gross margin—

Net margin—

Rev growth0.00%

EPS growth12.96%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value115.93M

Revenue210K

Net income-2.52M

Gross profit—

Free cash flow-7.19M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out34.02M

Employees4

ListedFri, Oct 7, 1983

Free float—

Float %—

Short interest—

Days to cover—

Short volume—

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeC

Conviction59 / 100

Pattern quality—

Tech rank57.9 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance3.77

Support2.61

Days since event—

Candle confirm—

News sentiment—

Financials as of Thu, Apr 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ANIX

All disclosures →

No recent disclosed trades by Congress in ANIX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ANIX · 7 buys

Insider	Side	Shares	Value	Traded	Filed
KUMAR AMIT Chief Executive Officer · Common Stock · 2026-07-27	Buy	5K	$17K	2026-07-27	2026-07-28
KUMAR AMIT Chief Executive Officer · Common Stock · 2026-07-27	Buy	3.19K	$11K	2026-07-27	2026-07-27
KUMAR AMIT Chief Executive Officer · Common Stock · 2026-07-24	Buy	3K	$11K	2026-07-24	2026-07-27
Titterton Lewis H jr Director · Common Stock · 2026-07-15	Buy	2.8K	$9K	2026-07-15	2026-07-16
KUMAR AMIT Chief Executive Officer · Common Stock · 2026-07-10	Buy	5K	$15K	2026-07-10	2026-07-13
Titterton Lewis H jr Director · Common Stock · 2026-06-16	Buy	2.84K	$7K	2026-06-16	2026-06-17
KUMAR AMIT Chief Executive Officer · Common Stock · 2026-06-12	Buy	21K	$53K	2026-06-12	2026-06-16

SEC filings

EDGAR filings in ANIX · 1 recent

EDGAR →

10-K/Q10-QQuarterly reportWed, Jun 10, 2026

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.